• Ulf Wiinberg

Ulf Wiinberg

Mr. Wiinberg has 20 years of senior leadership experience, most recently serving as Chief Executive Officer of H. Lundbeck A/S, a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders.

Ulf Wiinberg

He previously served on the boards of several healthcare industry associations and held multiple executive roles at Wyeth, one of the world’s largest research-driven pharmaceutical companies that was acquired by Pfizer in 2009.

At Wyeth, he served as

  • President of Europe, Africa and Middle East
  • President of Consumer Healthcare
  • Managing Director of Wyeth UK
  • in various commercial positions


Mr. Wiinberg currently serves on the boards of UCB SA, a global biopharmaceutical company based in Belgium, Avillion LLP (Chairman), a London-based drug development company, Hansa Medical AB (Chairman), a Swedish biopharmaceutical company, Alfa Laval AB, a Swedish industrial company, and Nestle Health Science